LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.

    Nowicki, Theodore S / Peters, Cole W / Quiros, Crystal / Kidd, Conner K / Kawakami, Moe / Klomhaus, Alexandra M / Baselga-Carretero, Ignacio / Kaplan-Lefko, Paula / Macabali, Mignonette H / Perez Garcilazo, Ivan / Berent-Maoz, Beata / Comin-Anduix, Begoña / Ribas, Antoni

    Cancer immunology research

    2023  Band 11, Heft 12, Seite(n) 1589–1597

    Abstract: Transgenic T-cell receptor (TCR) T cell-based adoptive cell therapies for solid tumors are associated with dramatic initial response rates, but there remain many instances of treatment failure and disease relapse. The association of infusion product ... ...

    Abstract Transgenic T-cell receptor (TCR) T cell-based adoptive cell therapies for solid tumors are associated with dramatic initial response rates, but there remain many instances of treatment failure and disease relapse. The association of infusion product cytokine profiles with clinical response has not been explored in the context of TCR T-cell therapy products. Single-cell antigen-dependent secretomic and proteomic analysis of preinfusion clinical TCR T-cell therapy products revealed that TNFα cytokine functionality of CD8+ T cells and phospho-STAT3 signaling in these cells were both associated with superior clinical responsiveness to therapy. By contrast, CD4+ T-helper 2 cell cytokine profiles were associated with inferior clinical responses. In parallel, preinfusion levels of IL15, Flt3-L, and CX3CL1 were all found to be associated with clinical response to therapy. These results have implications for the development of therapeutic biomarkers and identify potential targets for enrichment in the design of transgenic TCR T-cell therapies for solid tumors.
    Mesh-Begriff(e) Animals ; Humans ; Mice ; Tumor Necrosis Factor-alpha ; Proteomics ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; Cytokines ; Animals, Genetically Modified ; Neoplasms ; Cell- and Tissue-Based Therapy ; Mice, Transgenic ; STAT3 Transcription Factor
    Chemische Substanzen Tumor Necrosis Factor-alpha ; Receptors, Antigen, T-Cell ; Cytokines ; STAT3 protein, human ; STAT3 Transcription Factor
    Sprache Englisch
    Erscheinungsdatum 2023-10-21
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-23-0577
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade.

    Abril-Rodríguez, Gabriel / Torrejon, Davis Y / Karin, Daniel / Campbell, Katie M / Medina, Egmidio / Saco, Justin D / Galvez, Mildred / Champhekar, Ameya S / Perez-Garcilazo, Ivan / Baselga-Carretero, Ignacio / Singh, Jas / Comin-Anduix, Begoña / Puig-Saus, Cristina / Ribas, Antoni

    Cancer research communications

    2022  Band 2, Heft 10, Seite(n) 1214–1228

    Abstract: PAK4 inhibition can sensitize tumors to immune checkpoint blockade (ICB) therapy, however, the underlying mechanisms remain unclear. We report that PAK4 inhibition reverses immune cell exclusion by increasing the infiltration of CD8 T cells and ... ...

    Abstract PAK4 inhibition can sensitize tumors to immune checkpoint blockade (ICB) therapy, however, the underlying mechanisms remain unclear. We report that PAK4 inhibition reverses immune cell exclusion by increasing the infiltration of CD8 T cells and CD103
    Mesh-Begriff(e) Animals ; Mice ; Immune Checkpoint Inhibitors/pharmacology ; Tumor Microenvironment/genetics ; CD8-Positive T-Lymphocytes ; Melanoma/drug therapy ; Antigens, Neoplasm/pharmacology
    Chemische Substanzen Immune Checkpoint Inhibitors ; Antigens, Neoplasm
    Sprache Englisch
    Erscheinungsdatum 2022-10-19
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.crc-21-0133
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Neoantigen-targeted CD8

    Puig-Saus, Cristina / Sennino, Barbara / Peng, Songming / Wang, Clifford L / Pan, Zheng / Yuen, Benjamin / Purandare, Bhamini / An, Duo / Quach, Boi B / Nguyen, Diana / Xia, Huiming / Jilani, Sameeha / Shao, Kevin / McHugh, Claire / Greer, John / Peabody, Phillip / Nayak, Saparya / Hoover, Jonathan / Said, Sara /
    Jacoby, Kyle / Dalmas, Olivier / Foy, Susan P / Conroy, Andrew / Yi, Michael C / Shieh, Christine / Lu, William / Heeringa, Katharine / Ma, Yan / Chizari, Shahab / Pilling, Melissa J / Ting, Marc / Tunuguntla, Ramya / Sandoval, Salemiz / Moot, Robert / Hunter, Theresa / Zhao, Sidi / Saco, Justin D / Perez-Garcilazo, Ivan / Medina, Egmidio / Vega-Crespo, Agustin / Baselga-Carretero, Ignacio / Abril-Rodriguez, Gabriel / Cherry, Grace / Wong, Deborah J / Hundal, Jasreet / Chmielowski, Bartosz / Speiser, Daniel E / Bethune, Michael T / Bao, Xiaoyan R / Gros, Alena / Griffith, Obi L / Griffith, Malachi / Heath, James R / Franzusoff, Alex / Mandl, Stefanie J / Ribas, Antoni

    Nature

    2023  Band 615, Heft 7953, Seite(n) 697–704

    Abstract: Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T ... ...

    Abstract Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells
    Mesh-Begriff(e) Humans ; Antigens, Neoplasm/immunology ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Immunotherapy ; Melanoma/drug therapy ; Melanoma/genetics ; Melanoma/immunology ; Melanoma/pathology ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; HLA Antigens/immunology ; Neoplasm Metastasis ; Precision Medicine ; Gene Editing ; CRISPR-Cas Systems ; Mutation
    Chemische Substanzen Antigens, Neoplasm ; Receptors, Antigen, T-Cell ; Immune Checkpoint Inhibitors ; HLA Antigens ; PDCD1 protein, human
    Sprache Englisch
    Erscheinungsdatum 2023-03-08
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-023-05787-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Autoantibody Landscape in Patients with Advanced Prostate Cancer.

    Chen, William S / Haynes, Winston A / Waitz, Rebecca / Kamath, Kathy / Vega-Crespo, Agustin / Shrestha, Raunak / Zhang, Minlu / Foye, Adam / Baselga Carretero, Ignacio / Perez Garcilazo, Ivan / Zhang, Meng / Zhao, Shuang G / Sjöström, Martin / Quigley, David A / Chou, Jonathan / Beer, Tomasz M / Rettig, Matthew / Gleave, Martin / Evans, Christopher P /
    Lara, Primo / Chi, Kim N / Reiter, Robert E / Alumkal, Joshi J / Ashworth, Alan / Aggarwal, Rahul / Small, Eric J / Daugherty, Patrick S / Ribas, Antoni / Oh, David Y / Shon, John C / Feng, Felix Y

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2020  Band 26, Heft 23, Seite(n) 6204–6214

    Abstract: Purpose: Autoantibody responses in cancer are of great interest, as they may be concordant with T-cell responses to cancer antigens or predictive of response to cancer immunotherapies. Thus, we sought to characterize the antibody landscape of metastatic ...

    Abstract Purpose: Autoantibody responses in cancer are of great interest, as they may be concordant with T-cell responses to cancer antigens or predictive of response to cancer immunotherapies. Thus, we sought to characterize the antibody landscape of metastatic castration-resistant prostate cancer (mCRPC).
    Experimental design: Serum antibody epitope repertoire analysis (SERA) was performed on patient serum to identify tumor-specific neoepitopes. Somatic mutation-specific neoepitopes were investigated by associating serum epitope enrichment scores with whole-genome sequencing results from paired solid tumor metastasis biopsies and germline blood samples. A protein-based immunome-wide association study (PIWAS) was performed to identify significantly enriched epitopes, and candidate serum antibodies enriched in select patients were validated by ELISA profiling. A distinct cohort of patients with melanoma was evaluated to validate the top cancer-specific epitopes.
    Results: SERA was performed on 1,229 serum samples obtained from 72 men with mCRPC and 1,157 healthy control patients. Twenty-nine of 6,636 somatic mutations (0.44%) were associated with an antibody response specific to the mutated peptide. PIWAS analyses identified motifs in 11 proteins, including NY-ESO-1 and HERVK-113, as immunogenic in mCRPC, and ELISA confirmed serum antibody enrichment in candidate patients. Confirmatory PIWAS, Identifying Motifs Using Next-generation sequencing Experiments (IMUNE), and ELISA analyses performed on serum samples from 106 patients with melanoma similarly revealed enriched cancer-specific antibody responses to NY-ESO-1.
    Conclusions: We present the first large-scale profiling of autoantibodies in advanced prostate cancer, utilizing a new antibody profiling approach to reveal novel cancer-specific antigens and epitopes. Our study recovers antigens of known importance and identifies novel tumor-specific epitopes of translational interest.
    Mesh-Begriff(e) Aged ; Antigens, Neoplasm/immunology ; Autoantibodies/blood ; Autoantibodies/immunology ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/immunology ; Case-Control Studies ; Epitopes/immunology ; Follow-Up Studies ; Humans ; Male ; Mutation ; Prognosis ; Prospective Studies ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/immunology ; Prostatic Neoplasms/pathology
    Chemische Substanzen Antigens, Neoplasm ; Autoantibodies ; Biomarkers, Tumor ; Epitopes
    Sprache Englisch
    Erscheinungsdatum 2020-09-23
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-20-1966
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang